Ono Pharmaceutical Co., - Depositary Receipt (OPHLY) Price Target Decreased by 32.97% to 1.85

The average one-year price target for Ono Pharmaceutical Co. (OTCPK:OPHLY) has been sharply revised down by 32.97% to $1.85, now representing a 59.97% decrease from its current closing price of $4.62. This significant downgrade is accompanied by a notable decline in institutional interest, with the number of funds reporting positions decreasing by 11.11% and total institutional shares falling by 49.96% to 75K in the last quarter, signaling a broadly bearish shift in sentiment among institutional investors.

Analysis

The average one-year price target for Ono Pharmaceutical Co. (OTCPK:OPHLY) has been significantly reduced by 32.97% to $1.85 per share from a prior estimate of $2.76. This revised target now implies a substantial 59.97% downside from the latest reported closing price of $4.62, signaling a strong bearish outlook from analysts.

Institutional sentiment has also deteriorated, with the number of funds reporting positions in OPHLY decreasing by 11.11% in the last quarter. Concurrently, total shares owned by institutions saw a sharp decline of 49.96%, falling to 75K shares, indicating a broad institutional divestment trend.

While some individual holders like GAMMA Investing and Fulton Bank increased their share count, they simultaneously reduced their portfolio allocation to OPHLY, suggesting a cautious stance. Rhumbline Advisers notably decreased its holdings by 284.04% and portfolio allocation by 74.14%, reinforcing the overall negative institutional flow despite SPWO's increased allocation.

Key Decisions for Investors

• Investors should re-evaluate their positions in OPHLY given the substantial downward revision in the average price target and the significant institutional divestment.
• It may be prudent to monitor further analyst revisions and institutional flow data for stabilization.
• Consider risk mitigation strategies due to the implied downside from the current share price.